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Cystic Fibrosis airway disease  
 
Cystic Fibrosis (CF) is a lethal genetic disorder which results from 
a mutation of the gene coding for the Cystic Fibrosis Transmembrane 
conductance Regulator (CFTR), a cyclic AMP-dependent Cl- channel 
[ ].  Cystic Fibrosis affects various organs in which the CFTR 
protein is normally expressed.  The major clinical features of CF are 
chronic pulmonary disease, exocrine pancreatic insufficiency and male 
infertility, however, the lung disease is the main cause of morbidity 
and mortality in CF [2-4]. Healthy airways are lined by an epithelial 
layer that plays a major role in defense against inhaled pathogens 
involving several specialized epithelial functions including; mechanical 
barrier, adequate surface hydration due to an intricate regulation of 
ions and water transport, mucus secretion, production of 
antimicrobial peptides, expression of receptors that recognize 
pathogen associated molecular patterns (PAMPs), secretion of 
cytokines that control the local immune responses in the airway 
lumen. In CF mutations of the CFTR gene results in defective Cl- 
secretion and Na+ hyperabsorption by airway epithelia [5,6]. This 
contributes to reduction of the periciliary fluid volume, the airway 
lumen dehydration, reduction of the periciliary fluid volume and 
mucus plugging [7]. This results in an impaired mucociliary clearance 
of pathogens from the lung, favouring chronic bacterial colonization, 
persistent inflammation and progressive destruction of the lung [8]. In 
addition to the abnormality of epithelial ion transport, other epithelial 
dysfunctions have been described in chronically inflamed and infected 
CF airways, intrinsic pro-inflammatory properties, amplified 
inflammatory responses to infections and reduced bacterial clearance. 
However, beyond this general description, the pathogenesis of the CF 













Anti-inflammatory therapy in Cystic Fibrosis 
 
Whilst the field continues to celebrate the success, for a minority 
of people with CF, in achieving therapeutic benefits via CFTR 
modulation strategies, reduction of lung inflammation and restoration 
of airway hydration / muco-ciliary clearance remain core goals of CF 
therapy for the majority.  Several anti-inflammatory approaches have 
been examined in CF, however, the ideal anti-inflammatory drug is 
not yet available [9].  A recent systematic review of the risks and 
benefits of Inhaled corticosteroids (ICS) in CF, examining evidence 
from 3 trials, concluded that there is insufficient evidence to 
establish whether ICS are beneficial in CF, but withdrawal in those 
already taking them has been shown to be safe [ 0].  It is established 
that ICS use can have adverse effects on growth.  A systematic review 
of the efficacy of non-steroidal anti-inflammatory drugs in CF 
concluded that treatment with high-dose ibuprofen was associated 
with a significantly lower annual rate of decline in lung function 
(especially in children), however, the adoption of ibuprofen into 
therapy has not been universally accepted [ , 2].  Redressing the 
imbalance in fatty acid metabolism described in CF, by 
supplementation of Docosahexaenoic Acid may be helpful, and efforts 
are ongoing to evaluate the potential therapeutic benefit [ 3]. 
 
The Specialized Pro-resolving Mediators  
 
New perspectives have emerged in inflammation research with the 
discovery of new classes of biologically active lipid mediators playing 
specialised roles in the active resolution of inflammation – the 
“specialized pro-resolving mediators” (SPM) [ 4].  Furthermore, the 
acute inflammatory response is a protective mechanism that evolved to 
eliminate invading organisms and yet be self-limited with an active 
resolution phase designed to restore tissue homeostasis. The 
resolution phase is carried out by the actions of SPM which are non-
immunosuppressive [ 4].  The temporal evolution of acute 
inflammation toward its active resolution is directed by the sequential 
expression and activity of characteristic classes of eicosanoid mediator 
in a process termed “class switching” [ 5]. Prostaglandins are 
biosynthesised early, initiating the inflammatory response.  
Leukotrienes follow, typified by Leukotriene B4 (LTB4) which plays 
its role in amplification and propagation of inflammation [ 5] acting 
in concert with the cytokine Interleukin 8 (IL-8) as a potent 
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neutrophil chemo-attractant [ 6, 7].   Lipoxin A4 (LXA4) is the first 
eicosanoid of the SPM family to be expressed in the active resolution 
phase of inflammation. LXA4 production is followed by the 
biosynthesis of Resolvins and Protectins at the inflammatory site. 
These SPM are biosynthesized in vivo in inflammatory exudates from 
essential fatty acids; Lipoxins (LX) from arachidonic acid; E-series 
resolvins (Rv) from Omega-3 Eicosapentaenoic acid (EPA); D-series 
resolvins and protectins (PD) from Docosahexaenoic acid (DHA) 
[ 4].  
 
Anti-inflammatory properties of Lipoxin A4 
 
The anti-inflammatory properties of LXA4 have been reported in 
a wide variety of tissues.  LXA4 inhibits nuclear factor-kappaB 
activation, which results in inhibition of pro-inflammatory cytokine 
release and inhibition of inflammatory responses in microglial cells, 
astrocytoma cells, macrophages, peripheral blood mononuclear cells 
(PBMC), polymorphonuclear leukocytes (PMN) and intestinal 
epithelial cells  [ 8-20]. LXA4 inhibits neutrophil functions, most 
notably inhibiting LTB4 induced neutrophil chemotaxis, neutrophil 
adherence and transmigration across intestinal epithelium and 
endothelium and inhibiting superoxide anion and peroxynitrite 
generation [ 4] [2 -23].  LXA4 facilitate neutrophil apoptosis [24] 
and stimulates phagocytosis of apoptotic neutrophils by macrophages 
[25][26]. This is a critical point since delayed neutrophil apoptosis 
appears to be a component of the pathophysiology in patients with 
inflammatory diseases, including cystic fibrosis [27,28] and frequently 
correlates with disease severity and outcome.  In the airways, in vitro 
and in vivo studies also report that LXA4 displays diverse and potent 
anti-inflammatory actions [ 9,29,30]. In human airways, LXA4 
suppresses IL-8 production by leukocytes and bronchial epithelial 
cells [30,3 ].  LXA4 was shown to arrest neutrophilic inflammation 
and decrease infection in a mouse model of chronic airway 
inflammation and infection [32].  LXA4 has been proposed as a novel 
regulators of adaptive immunity and may have therapeutic potential in 
chronic immune disorders [33]. The pro-resolution properties of 
LXA4 are mediated by the ALX/FPR2 receptor. The ALX/FPR2 is 
a G protein-coupled receptor of seven-transmembrane domains that is 
expressed mainly by mammalian phagocytic leukocytes. The known 
effect of ALX/FPR2 receptor in  the  in host defense and 
inflammation is not only triggered by LXA4 since other pro-
resolution mediators such as resolving D  also mediate their effects 
through this receptor [34] [35] .  
 
Abnormal eicosanoid class switching in Cystic Fibrosis 
 
LXA4 is produced by lipoxygenase (LO) interactions resulting 
from trans-cellular cooperations  [36] of neutrophils [37], eosinophils 
[38], alveolar macrophages [39], platelets [40] or airway epithelial 
cells [4 ], each expressing different Lipoxygenase (LO) enzymes 
which act in sequence in LXA4 biosynthesis [ 6,42].  The 5-LO 
expressed by neutrophils can utilise the 5(S)-hydroxyeicosatetranoic 
acid released by epithelial cells as substrate to synthesize lipoxins [37]. 
The platelet 2-LO [40], the macrophages or epithelial 5-LO [39] 
[ 9] are each able to transform Leukotriene A4, released by 
neutrophils, into LXA4. Up-regulation of 5-LO activity generates an 
inverse relationship between LTB4 and LXA4 biosynthesis. The 
activity of 5-LO promotes LXA4 biosynthesis and blocks 
leukotriene biosynthesis, both as a result of 5-LO products 
competing for flux at the 5-LO level, and by diversion of the 
intermediate Leukotriene A4 away from LTB4 towards LXA4 
biosynthesis [ 5,4 ,42].   The levels of LXA4 have been reported to 
be decreased in chronic airway inflammatory disease such as asthma, 
chronic obstructive pulmonary disease and CF [29,32,43,44]. A 
decreased proportion of pro-resolving compounds (LXA4) compared 
to pro-inflammatory (LTB4) is associated with decrease of lung 
function [45].  The absolute content of LXA4 concentration in CF 
BAL fluid  from patients with CF is not significantly different from 
controls [46]. However, a significant suppression in LXA4/neutrophil 
ratios in BAL fluid of patients with CF compared with pulmonary 
inflammatory controls was reported [32,46].  More specifically, in 
vitro studies support a role for CFTR in LXA4 production. CFTR 
inhibition reduced LXA4 synthesis by 50% during platelets/ PMN 
co-incubation by inhibiting the lipoxin synthase activity of platelets 
2-LO.  Platelets from patients with CF generated 40% less LXA4 
compared to healthy subject [47].  The decreased LXA4 production in 
CF provides a mechanistic explanation of the failure to actively 









Lipoxin A4 regulates ion transport and the airway surface liquid 
height 
 
LXA4 stimulates a rapid and transient intracellular Ca2+ increase 
and induces Cl- secretion through human bronchial epithelial cells by 
Ca2+-activated Cl- channel and not CFTR  [48]. Furthermore, LXA4 
effects on ion transport lead into an increase of the airway surface 
liquid (ASL) layer height in models of fully differentiated bronchial 
epithelia derived from primary culture of bronchial brushings from 
patients with CF (Figure ). LXA4 exerts this effect on the ASL 
dynamics via the ALX/FPR2 receptor which is expressed in the 
apical membrane of airway epithelial cells. The sustained increase in 
ASL height induced by LXA4 in non-CF and CF bronchial epithelial 
results from stimulation of an intracellular calcium signal and Ca2+-
activated Cl- secretion via NPPB sensitive Cl- channels [49]. LXA4 
thus restores Cl- secretion and adequate ASL height which are affected 
in CF airways, highlighting a role for LXA4 in the control of innate 
immune defence. The inadequate endogenous LXA4 biosynthesis in 
CF contributes to the reduce ASL volume and impaired mucociliary 
clearance in addition to alter resolution of inflammation in the airway, 
thus amplifying the vicious circle of airway dehydration, chronic 
infection and inflammation.   
 
Lipoxin A4 regulates airway epithelial integrity 
 
Epithelial repair is a key process required to maintain epithelial 
barrier integrity and respiratory function, however in CF, repeated 
Figure 1. LXA4 restores the Airway Surface Liquid (ASL) layer in CF 
bronchial epithelium. Live cell imaging using confocal microscopy of 
bronchial epithelium in primary culture from a child with CF before and 
after treatment with LXA4. The bronchial epithelial cells are stained in 
green using calcein green and the ASL in red using dextran coupled to 
texas-red. 
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infections and inflammatory insults result in damage to the airways, 
triggering the repair process [50]. Epithelial repair initially involves 
cell spreading and migration, followed by proliferation to repopulate 
the denuded area that has been created by injury [5 -53]. This is then 
followed by differentiation of the epithelium [54]. Recent research 
suggests that epithelial repair and differentiation of the CF airway 
epithelium is down-regulated or delayed [55-59]. More specifically, 
cell migration and proliferation appear to both be reduced during 
repair in CF bronchial epithelial cells compared to non-CF [60]. This 
delay in repair of the CF epithelium renders the lung more susceptible 
to ongoing bacterial infection and thus may lead to more epithelial 
damage [6 ]. It was recently reported that LXA4 can trigger epithelial 
cell migration and proliferation and thus play a role in repair of 
corneal and bronchial epithelia [62-64] [65-67]. LXA4 triggers an 
increase in migration, proliferation, and wound repair of non-CF and 
CF bronchial epithelia. These responses to LXA4 are mediated by the 
ALX/FPR2 receptor via the downstream activation of KATP channels 
and ERK MAP kinase phosphorylation [60]. This effect of LXA4 
both ion transport and repair are consistent with the role of ion 
channels in two key processes of repair, migration and proliferation 
[68]. In particular potassium channels have been shown in numerous 
cell types to be involved in cell migration and proliferation [57,58,69-
72]. Furthermore, LXA4 enhances airway epithelial tight junction 
formation. LXA4 stimulates ZO- , claudin-  and occludin expression 
and trafficking at the apical membrane resulting in enhanced 
transepithelial electrical resistance in human airway epithelia [73].  
Therefore the reduced levels of LXA4 in the CF airways  [74] may 









Therapeutic potential for LXA4 in cystic fibrosis treatment 
 
Clearance of airway secretions has been a first line therapy for 
patients with CF and a variety of airway clearance therapies have been 
developed [75,76]. One of the greatest challenges into reversing the 
CF defect in the airways is to design strategies to overcome the 
absence of functional CFTR by stimulating chloride secretion via 
alternative pathways, thus restoring airway hydration and mucociliary 
clearance. This can be achieved via the activity of calcium-activated 
chloride channels stimulated by agents that raise the intracellular 
calcium concentration. This strategy has been plagued by the 
attendant side effects of the amplification of the calcium dependant 
pro-inflammatory response resulting in the undesirable activation of 
NFĸB [26]. Thus identification of agents, particularly natural 
endogenous biologicals, that stimulate alternative non-CFTR Cl- 
secretory pathways and promote ASL hydration and optimal ASL 
height recovery are likely to be of therapeutic benefit in improving 
mucociliary clearance in patients with CF. The effects of LXA4 
inhalation has been evaluated in a pilot study of eight asthmatic and 
healthy adult subjects. The challenge was tolerated, had no adverse 
effect on pulse or blood pressure and demonstrated favourable effects 
on specific airway conductance [77].  
 
Conclusion and future prospect 
 
Taken together, the discovery of the multiple LXA4 functions in 
restoring bronchial epithelium ion transport in enhancing ASL height, 
in restoring epithelial barrier function and in reducing inflammation 
might provide significant advance in improving quality of life and 




















Figure 2. Pleiotropic effects of LXA4. LXA4 which is abnormally produced in 
Cystic Fibrosis controls various airway physiological functions. LXA4 
regulates bronchial epithelium ion transport, enhances the airway surface 
liquid (ASL) height, protects epithelial barrier integrity and reduces 
inflammation. 
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